SummaryPfizer-developed Paxlovid is a combination of two medicines. Nirmatrelvir, which blocks a key viral enzyme needed for SARS-CoV-2 to replicate, andritonavir, which slows the breakdown of nirmatrelvir in the body, allowing it to remain effective for longer.